Pharmacogenomics in epilepsy care across Asia

Review of applicable pharmacogenomic associations in Asian epileptology: severe cutaneous reactions to aromatic AEDs, phenytoin and clobazam metabolism

Pharmacogenomics of antiepileptic drugs in Asia is reviewed, focusing on HLA-B*15:01 and HLA-A*31:01 — alleles with markedly higher frequencies in Asian populations — and their role in predicting severe cutaneous adverse reactions to aromatic AEDs (carbamazepine, phenytoin, lamotrigine). CYP enzyme pharmacogenetics for phenytoin and clobazam metabolism are also covered. Clinical recommendations adapted to Asian healthcare contexts are provided.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

AED pharmacogenomics is one of the fields where the impact of allele frequency differences between populations is strongest: HLA-B*15:01 is up to 10× more frequent in certain Asian populations than in Europeans, making pre-treatment genotyping a strong recommendation in Asia (CPIC level A for carbamazepine). This region-specific review is valuable for clinicians managing Asian patients.

Clinical impact : 2/3 · Evidence strength : 2/3 · Novelty : 1/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 7/10